- Details
- Cora Sternberg, MD, FACP, shares her experiences from the CARD study, which was the first trial to evaluate the sequencing of the androgen-signaling–targeted inhibitor (abiraterone or enzalutamide) compared to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) who had been previously treated with docetaxel and the alternative androgen-signaling–targeted agent (abi...
|
- Details
- Following presentations at the ASCO 2020 Virtual Annual Meeting, Toni Choueiri, MD, discusses the SAVOIR, COSMIC-313, and OMNIVORE kidney cancer studies. COSMIC-313 is a phase III study of cabozantinib in combination with nivolumab and ipilimumab in patients with untreated advanced renal cell carcinoma. The phase II OMNIVORE study enrolled patients with advanced RCC and no prior checkpoint inhibit...
|
- Details
- Ali Khaki and Petros Grivas come together to discuss a study Ali Khaki presented at the 2020 ASCO meeting, on the cost-effectiveness of atezolizumab added to first-line platinum chemotherapy for Advanced Urothelial Cancer. He with Dr. Grivas provides further insight into how this treatment plan was assessed, while also giving context regarding how cost-effectiveness is measured in cancer patients....
|
- Details
- Darolutamide is a structurally unique androgen-receptor antagonist that is approved for the treatment of prostate cancer. ARAMIS is a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer, and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 ratio to receive daroluta...
|
- Details
- Rana McKay joins Alicia Morgans to discuss the outcomes of a study investigating randomized patients with high-risk prostate cancer (Gleason ≥4+3, PSA > 20, T3 disease, and lymph nodes
|
- Details
- Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels. Neal Shore joins Alicia Morgans to discuss the results of the HERO phase 3 trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. Relugolix is an oral, once a day medication, and the trial had a primary endpoint of non...
|
- Details
- The current standard of care for patients with localized muscle-invasive bladder cancer involves neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Unfortunately, even with chemotherapy and surgery, cancer recurrence is common, with a 5-year survival rate of 50—60%. Thus, additional strategies are necessary to help patients achieve long term survival. Thomas Powles and Matthe...
|
- Details
- The phase III JAVELIN Bladder 100 trial was the first urothelial carcinoma plenary session at an ASCO annual meeting in the meeting's history and Thomas Powles lead principal investigator on the trial along with Matthew Galsky join Alicia Morgans sharing results of this trial. This was a maintenance trial where first-line treatment with avelumab extended the survival over best supportive care (BSC...
|
- Details
- Clear cell renal carcinoma has a modest tumor mutational burden and increased infiltration of CD8+ T cells which is associated with worse prognosis in this disease. Biomarkers for response to immune checkpoint inhibitors are needed to predict which patients will respond. David Braun joins Alicia Morgans and overviews his ASCO 2020 presentation on the genomic and immune determinants of response to...
|
- Details
- Mary-Ellen Taplin, Professor of Medicine Harvard Medical School and a GU Medical Oncologist at the Dana-Farber Cancer Institute, joins Alicia Morgans to discuss the ProGen study. A randomized controlled trial that aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer. This...
|
